ORDER GRANTING MOTIONS TO DISMISS
I. INTRODUCTION
Now before the Court is the above-captioned Defendants’ motions to dismiss Plaintiff the Florey Institute of Neuroscience and Mental Health’s (“Plaintiff’) first amended complaint. ECF No. 43 (“FAC”). All Defendants except Thomas G. Wiggans join in one motion to dismiss, ECF No. 53 (“KPCB MTD”), while Mr. Wiggans filed his own motion, ECF No. 77 (‘Wiggans MTD”).
II. BACKGROUND
The Court summarized the facts of this case in its September 26, 2013 Order. ECF No. 41 (“Sept. 26 Order”). It repeats some of the germane facts below, followed by a procedural summary.
A. Factual Background
In 1982, Plaintiff entered a research collaboration and IP licensing agreement with Genentech. FAC ¶¶ 28-31. The agreement concerned Plaintiffs extensive work on the relaxin peptide, whose many uses include treating acute heart failure. Id. ¶¶ 1-11. In 1993, Genentech established a separate entity that became Con-nectics Corporation (“CNCT”). Id. ¶ 32. CNCT was tasked with working on Genen-tech’s relaxin projects. Id. That same year, Plaintiff granted Genentech’s request to sublicense Plaintiffs intellectual property to CNCT, as it was required to do under the contract at the time. Id. ¶ 34. In 1994 that agreement was replaced by an amendment that granted Genentech the right to receive royalties on any licensed product sales by CNCT, and CNCT in turn agreed to pay Plaintiff royalties and other payments that would be due from Genentech per the 1982 Agreement. Id. ¶ 30.
In 1995, CNCT informed Plaintiff in a letter from Defendant Wiggans (then the CNCT CEO and president) that it wanted to enter a new research agreement with Plaintiff. Id. ¶ 35. CNCT wanted to reduce the royalty rate under the existing contracts, because it believed the high rate would deter corporate drug-development partners, so it proposed reducing the royalty rate and adding terms that would give Plaintiff a share of future up-front and milestone payments paid by CNCT’s future drug-development partners. Id. CNCT and Plaintiff negotiated between 1995 and 1998, after which they reached an agreement. Id. ¶¶ 32-35 & Ex. 1 (“1998 Agreement”). The 1998 Agreement reduced future royalty payments, but guaranteed Plaintiff 1 percent of future upfront payments and 15 percent of later milestone payments. Id. ¶ 38; 1998 Agreement § 5.2.
During the negotiations, Plaintiff expressed concerns that CNCT might try to avoid future payment obligations by structuring future drug development agreements and related payments to avoid the parties’ intent. Id. ¶ 38. Plaintiff contends that it sought assurances to this effect from CNCT, after which “CNCT reassured [Plaintiff] that its concerns were unfounded, stating that CNCT would not attempt to convince a drug development company partner to restructure any future payments so as to avoid the duty to compensate [Plaintiff] for its relaxin know-how and related patent rights, and also pointed out that the duty to compensate [Plaintiff] would be apparent from the structuring of any future relationships and the nature, timing, and conditions for future payments from any drug development partner.” Id.
In 2001, CNCT ceased its development efforts after its clinical trials for scleroder-ma — its focus on relaxin research up to that point — were deemed unsuccessful. Id. ¶¶ 45-46. In 2002, CNCT’s relaxin team established a new commercial entity, Corthera (at first called BAS Medical, Inc.). Id. In 2003, Defendants Kleiner Perkins and Breining, a Corthera founder, approached Plaintiff to seek assignment of the relaxin-related license from CNCT to Corthera. Id. ¶¶ 46-47.
In July 2003, Corthera negotiated an amendment to the 1998 Agreement that extended the agreement’s terms, permitted assignment of CNCT’s rights and obligations under the 1998 Agreement to Corthera, and further reduced Plaintiffs royalty rates to 2 percent of net sales. Id. ¶¶ 48-49 & Ex. 2 (“2003 Amendment”).
From 2003 through 2009, Plaintiff and Corthera collaborated on relaxin research. Id. ¶¶ 51-52. Plaintiff alleges that throughout this time, Defendants knew that Plaintiff was working on Corthera’s relaxin projects and that Plaintiff had granted Corthera a license to its relaxin patents in expectation of future payments. See ¶ 52. During this period, in 2007, Corthera hired Defendant Abel as its new CEO and changed its focus from dermatology applications to cardiovascular treatments. Id. ¶ 53. In May 2008, Corthera reported that ongoing clinical trials indicated that relaxin could prove beneficial for cardiac treatment, and in March 2009, Corthera completed those clinical trials, demonstrating positive results for relaxin in patients with acute heart failure. Id. ¶¶ 54-55. It initiated phase III clinical trials in October 2009. Id.
Shortly thereafter, in December 2009, Plaintiff learned from a press release issued by Corthera’s outside counsel, Kaye Scholer, that the pharmaceutical company Novartis had agreed to purchase Corthera up-front for $120 million in cash, characterized as a stock-purchase agreement that would leave Corthera as a wholly owned subsidiary of Novartis. Id. ¶ 56 & Ex. 3 (“Dec. Press Release”). Under the Novartis-Corthera agreement, Novartis was to make ádditional milestone payments of up to $500 million to the Corthera shareholders (not Corthera itself). Id. In January 2010, Novartis purchased all of Corthera’s stock, and its outside counsel issued a press release stating that Novartis had acquired “exclusive worldwide rights to re-laxin ... through the acquisition of ... Corthera, Inc.” Id. Exs. 4 (“Novartis. Agreement”), 5 (“Kaye Scholer Press Re
B. Procedural Background
Plaintiff originally pled four causes of action against all Defendants except the New Defendants and Mr. Wiggans: (1) conversion, (2) misappropriation, (3) unjust enrichment, and (4) constructive trust. Defendants moved to dismiss, and the Court granted that motion in part and denied it' in part. Sept. 26 Order at 1.
The Court held, first, that no assignment occurred in the Corthera-Novartis deal as a matter of law. Id. at 12-13. Second, as to conversion, the Court held that Plaintiff failed to state a claim because it did not sufficiently plead what Defendants had allegedly converted: IP or some unspecified payment right. See id. at 13-14. Third, the Court held that Plaintiff failed to state a claim for misappropriation because its pleadings were unacceptably vague as to what had been misappropriated and who misappropriated it, partly because Plaintiffs misappropriation claim relied on its conversion claim. Id. at 14-16. Finally, the Court rejected Defendants’ motion to dismiss Plaintiffs unjust enrichment claim in part because Defendants had mischaracterized Plaintiffs claim, rendering their arguments in-apposite. See id. at 16-17. The Court allowed Plaintiff to plead the unjust enrichment claim in the alternative. Id. at 18.
Now, based on the facts described above from Plaintiffs FAC, Plaintiff asserts four causes of action against Defendants: (1) conversion of intellectual property, (2) conversion of proceeds owed to Plaintiff, (3) misappropriation, and (4) unjust enrichment under quasi-contract. Defendants move to dismiss. The two motions to dismiss now focus primarily on. whether Plaintiff has stated claims under those four causes of action, and whether Plaintiffs claims might be preempted by various intellectual property laws.
III. LEGAL STANDARD
A motion to dismiss under Federal Rule of Civil Procedure 12(b)(6) “tests the legal sufficiency of a claim.” Navarro v. Block,
IV. DISCUSSION
A. Rule 8
Plaintiffs allegations against the New Defendants, including Defendant Wiggans, fail under Rule 8. In making this conclusion, the Court relies on a close reading of Plaintiffs complaint and controlling Supreme Court precedent. “Determining whether a complaint states a plausible claim for relief will ... be a context-specific task that requires the reviewing court to
In this case, Defendants did not originally challenge Plaintiffs pleadings under Rule 8. This time they do, though it is unclear whether Defendants raise it for both the Original and New Defendants, or just for the New Defendants. See KPCB MTD at 11-12; KPCB Reply at 1. Defendant Wiggans raises the issue for himself. Wiggans Reply at 3. As to all Defendants except the New Defendants and Defendant Wiggans, the Court rejects the Rule 8 challenge.
However, Plaintiffs pleadings are factually deficient as to the New Defendants and Defendant Wiggans, because while Plaintiff explains who those Defendants are, none of Plaintiffs allegations explain what they did or why it was wrong in a way specific enough to satisfy Rule 8. While Plaintiff explains, for example, what Defendant Wiggans’s roles were, FAC ¶¶ 23, 32, and that he communicated with Plaintiff about changes to the payment structure in the agreements, id. ¶ 35, made statements about the CNCTCorthera license, id. ¶ 50, and was a member of Corthera’s board, id. ¶ 58, at no point does the FAC plausibly explain-how Defendant Wiggans did anything actionable.
Further, there is virtually nothing specific in the FAC as to what the New Defendants did. Plaintiff states that it added those parties because they held significant stock in Corthera and received most of the payments made by Novartis, but this is hardly actionable behavior.
Plaintiffs claims as to the New Defendants and Defendant Wiggans are DISMISSED. As explained below, since Plaintiff also fails to state claims against any Defendant regardless of whether Plaintiff satisfied Rule 8 as to Defendant Wiggans or the New Defendants, the dismissal is WITH PREJUDICE.
B. Conversion
Plaintiff previously claimed that Defendant converted an undifferentiated mix of intellectual property and rights to payment. Plaintiff now divides its conversion claim into two parts: conversion of intellectual property, and conversion of proceeds owed to Plaintiff.
A conversion claim arises where there is an “act of dominion wrongfully exerted over another’s personal property in denial of or inconsistent with his rights therein.” Weiss v. Marcus,
The elements of a claim for conversion are (1) ownership or right to possession of property, (2) wrongful disposition of the property right, and (3) damages. Kremen v. Cohen,
i. Conversion of Intellectual Property
Plaintiffs conversion of intellectual property claim is premised on Defendants’ alleged disposal of Plaintiffs domestic and foreign relaxin patents, as well as of Plaintiffs relaxin-related. know-how. FAC ¶¶ 70-72. Defendants allegedly accomplished this by giving, transferring, and assigning to Novartis, “by implication if not expressly, the right to use [Plaintiffs] know-how” in a way that denied Plaintiff compensation, and also by depriving Plaintiff of its exclusive right to license its foreign and domestic patents. Id. ¶¶72-75.
Plaintiff first acknowledges that the Court held in its September 26 Order that a reverse triangular merger does not necessarily effect assignment as a matter of law from the acquired company to its acquirer. Opp’n to KPCB at 12 (citing Sept. 26 Order at 12-13). Plaintiff now argues that it sufficiently alleged assignment as a matter of fact or assignment by implication, meaning that Defendants objectively intended to transfer Plaintiffs rights from Corthera to Novartis. Id. at 12-13. On this point, Plaintiff continues to rely on an assignment theory, stating that regardless of the Court’s holding on assignment as a matter of law, Defendants effected an assignment in fact, or an assignment by implication, of Plaintiffs licensed intellectual property from Corthera to Novartis. Id. at 13-14.
Defendants respond that “assignments in fact” or “implied assignments” do not exist as legal concepts, and that Plaintiff is barred from raising the issue due to the Court’s prior order on the assignment issue. KPCB Reply at 6-7. Defendants also contend that because Plaintiff contradicts itself in asserting that any assignment was ineffective regardless of intentions, the claim for conversion of intellectual property must fail. Id. at 7 (citing Opp’n to KPCB at 12-13 & n.3). Further, Defendants note that the Merger Agreement itself states that Corthera would use diligent efforts to develop and sell pharmaceuticals, and contend that nothing in that Agreement says anything about Novartis itself developing or having the right to develop a relaxin-based drug, indicating that Corthera remains licensee and no intellectual property has been either assigned or converted. See id. at 7-8 (citing Merger Agreement ¶ 9.3). Finally, Defendants dispute Plaintiffs interpretation of the 2003 Amendment as voiding any transfer without Plaintiffs consent, because part of that contract permits non-consensual assignment in the event of a complete stock purchase.
As a threshold issue, the Court does not find that its holding on assignment as a-matter of law would necessarily bar Plaintiff from making a different argument about assignment. The original round of briefing on this matter concerned whether the reverse triangular merger itself effect
However, the Court does not find Plaintiffs new position convincing. Plaintiff contends that Defendants assigned Corthera’s license as a matter of fact. But in the same section Plaintiff maintains that “such an assignment, while clearly intended by Defendants and Novartis, was ineffective,” based on Section 6.6 of the 2003 Amendment’s provision non-assignment clause, which voids assignments made' without Plaintiffs consent (with exceptions, noted below). Opp’n to KPCB at 12 & n.3. In this context, Plaintiff contradicts itself to the point of implausibility. Plaintiffs theory depends on an assignment or transfer having taken place, but Plaintiffs position is that no assignment was possible under any circumstances. See FAC ¶¶ 56, 61, 65, 70, 72.
Plaintiff and Defendants also raise the issue of Section 6.6(b), which reads in relevant part:
[EJither party may assign, upon written notice to the other, both the rights and obligations of the [1998 Agreement] to the surviving corporation (“Surviving Party”) in any acquisition, merger or consolidation to which it is a party or to any person who acquires all or substantially all of its capital stock or assets or of the assets of that portion of such party’s business as to which the [1998, Agreement] pertains so long as such party (i) is reasonably determined to be financially able to fulfill its obligations under this Agreement; and (ii) does not materially impair the reputation of [Plaintiff].
Plaintiff states that nothing in that exception would preclude Plaintiff from being entitled to its share of payments in the event of a partnership agreement. Opp’n to KPCB at 15 n.6. That might be true, but Plaintiff pled that it never received notice under Section 6.6 or any other provision, and Plaintiffs argument is not that a partnership agreement took place — its position has always been that the merger was a ruse for Corthera and Novartis to become “partners” without legally triggering the payment provision of the contract.
Even if the Court were to evaluate the entire transaction and the parties’ conduct, as Plaintiff states is necessary per McCown v. Spencer,
Finally, to the extent Plaintiff suggests that the Corthera-Novartis merger itself effected an assignment, the Court’s September 26 Order on that issue is law of the case. The Court declines to revisit it.
Plaintiff does not further explain how its pleadings, absent an assignment theory, indicate how Defendants had anything to do with the conversion of Plaintiffs intellectual property rights. Plaintiff continues to rely on Defendants’ alleged role in the Novartis merger. Opp’n at 14-15 (citing FAC ¶¶ 35-36, 38-40, 44, 46-51, 56-58-63, 72). Plaintiff has alleged nothing concerning its intellectual property distinct from the merger, so it appears that nothing else in Plaintiffs FAC could support a conversion of intellectual property claim. Beyond these allegations, Plaintiffs claims are implausible, impermissibly vague, and fail to state a claim — the only plausible inference as to conversion of intellectual property, based on Plaintiffs facts, would point toward Plaintiff suing Corthera or Novartis, not Defendants. The Court declines to address the parties’ preemption arguments at this time.
Plaintiffs conversion of intellectual property claim is DISMISSED WITH PREJUDICE, because the Court finds that further amendment on this claim would be futile.
ii. Conversion of Proceeds Owed
Plaintiffs claim for conversion of proceeds owed is based on Plaintiffs alleged reliance on Defendants’ promise that Plaintiff would receive the agreed percentages of up-front and milestone payments from drug development partners, per the Agreements. FAC ¶ 77. Plaintiff pleads that it relied on those representations, and that both parties conducted themselves in accordance with the earlier promises and expectations. Id. ¶¶ 78-79. Defendants characterize Plaintiffs claim for conversion of proceeds owed as being an impermissible attempt to recover a right of payment under the Agreements, which is barred by California law. Defendants also contend that Plaintiffs claims are barred by the Agreements’ integration clause and the parol evidence rule. Plaintiff responds that its claims are not based on the Agreements, that the parol evidence rule does not foreclose its claims primarily because they are not based on the Agreements, and that the integration clause does not bar its claims because of the same reasons and because Defendants are not parties to the Agreements. See Opp’n to Wiggans at 12-19; Opp’n to KPCB at 15-19. Plaintiff also contends that the Court should interpret its conversion of proceeds claim as a claim for the imposition of an equitable lien, or alternatively as a claim for monies had and received. Opp’n at 16 & n.8.
Money cannot be the basis of a cause of action for conversion unless there is a “specific, identifiable sum involved, such as where an agent accepts a sum of
Plaintiff relies primarily on an analogy to' McCafferty v. Gilbank,
The Court does not find McCafferty an apt analogy to this case. While the defendant in McCafferty was, like Defendants here, not himself a party to any contract, he promised plaintiff a specific portion of a specific payment, and drafted a contract to that effect. Id. at 575-76,
Further, Plaintiff has not established that Defendants, as a virtually undifferentiated group, all knew about the vague promises made -in the 1998 Agreement or 2003 Amendment negotiations, especially when Defendants all enter and exit this fact pattern at various times, having come and gone as board members, employees, or investors at times not always made clear in the FAC. Neither equity nor the facts support this, especially since Plaintiff first contended that it was the CEO of CNCT who had made the promise, but Plaintiff now pleads more vaguely that it was “CNCT” who “reassured” Plaintiff about future payments, which does not support the contention either that Defendants themselves knew of any promise, or that it is plausible for the Court to find that any Defendant .promised Plaintiff anything particular at all. Plaintiffs FAC fails to allege reasonable or plausible grounds for
Finally, in terms of equity, if Plaintiff were seeking recovery of Partner payments against Corthera or Novartis its theory would be more plausible, but as pled here it appears to be an attempt to avoid those avenues for repayment. See Zerin,
Separately, the Court rejects Plaintiffs footnotes argument that the Court should interpret its conversion of proceeds claim as a claim for money had and received. Opp’n at 16 n.8. The Court agrees that plaintiffs need not correctly name each of their actions so long as the facts alleged support a claim, Self Directed Placement Corp. v. Control Data Corp.,
Plaintiffs conversion of payment owed claim is DISMISSED WITH PREJUDICE, since amendment would be futile.
C. Parol Evidence
Apart from the legal and pleading deficiencies described above, Plaintiffs arguments based on promises allegedly made during negotiations for the 1998 Agreement and 2003 Amendment are barred by the parol evidence rule. Plaintiff argues first that Defendants do not have standing to rely on the parol evidence rule, since they were not parties to the Agreements. Plaintiff also contends that if the Court finds the parol evidence rule applicable, it still does not bar Plaintiffs theory because Plaintiffs claims are not based on the Agreements, that its theory based on the earlier promises would not modify the
As a threshold matter, Plaintiff contends that Defendants cannot raise an argument based on the integration clause because they are not parties to the Agreements. Opp’n at 8-9. The Court rejects this argument. Plaintiff is suing Defendants based on the Agreements, and Plaintiffs authority does not support its position that non-parties cannot invoke the parol evidence rule or integrated contracts when the contracts are central to the issue at hand. See Thomson v. Canyon,
Substantively, Plaintiffs first two arguments are addressed in the venerable Supreme Court case Seitz v. Brewers’ Refrigerating Machine Co.,
Undoubtedly, the existence of a separate oral agreement as to any matter on which a written contract is silent, and which is not inconsistent with its terms, may be proven by parol, if, under the circumstances of the particular case, it may properly by inferred that the parties did not intend the written paper to be a complete and final statement of the whole of the transaction between them. But such an agreement must not only be collateral, but must relate to a subject distinct from that to which the written contract applies; that is, it must not be so closely connected with the principal transaction as to form part and parcel of it. And when the writing itself upon its face is couched in such terms as import a complete legal obligation, without any uncertainty as to the object or extent of the engagement, it is conclusively presumed that the whole engagement of the parties, and the extent and manner of their undertaking, was reduced to writing.
In other words, extrinsic evidence relating to a term not actually included in a contract — like a promise made during a negotiation — is sometimes permissible if the contract is not integrated and the evidence concerns a matter distinct from the contract. See id. But if that evidence is “so closely connected with the principal transaction as to form part and parcel of it,” and the agreement is integrated, the evidence is barred. See id.
Plaintiffs first argument — that the parol evidence rule is inapplicable because Plaintiffs claims and the underlying promises are not based on the Agreements — appears compelling at first, since the parties do not focus on how the parol evidence rule might apply to extrinsic evi
Plaintiffs second argument, that Defendants’ alleged promises not to structure future arrangements in ways that would evade the Agreements do not modify or contradict the Agreements, is also incorrect. First, to the extent that Plaintiff seeks to use the 1998 and 2003 promises as extrinsic evidence supporting an interpretation of the Corthera-Novartis deal as a “Partnership” under the Agreements, thereby triggering a payment obligation, Plaintiffs theory would modify or contradict the Agreements, which are clear and not capable of Plaintiffs new interpretation. The Agreements, as noted above, cognize both partnerships and acquisitions; and per Plaintiffs pleadings, the negotiating parties discussed but did not include clauses governing the situation that has now arisen between these parties. Second, because' the promises on which Plaintiff bases its claims were clearly topics of discussion during the Agreements’ negotiations, Plaintiffs reliance on the promises for its licensing and payment theories would modify the Agreements by adding terms specifically discussed but not added to the Agreements.
. Finally, Plaintiffs third argument — that the Court should admit extrinsic evidence to interpret the Agreements — is wrong. The Agreements are not reasonably susceptible of the meaning Plaintiff proffers. See Brinderson-Newberg Joint Venture v. Pac. Erectors, Inc.,
Therefore, the Court finds that Plaintiffs claims are barred by the parol evidence rule.
D. Misappropriation
Plaintiff contends that its claim succeeds based on its conversion claims as to the proceeds of the Novartis transaction, but the Court finds to the contrary. Plaintiffs misappropriation claim only restates its conversion claims, and it fails for the same reasons. It is DISMISSED WITH PREJUDICE, because the Court finds that amendment would be futile.
E. Unjust Enrichment
Plaintiff maintains that it has a claim for unjust enrichment or quasi-contract, the elements of which are (1) a defendant’s receipt of a benefit and (2) unjust retention of that benefit at the plaintiffs expense. Peterson v. Cellco P’ship,
In its September 26 Order, the Court rejected some of the Defendants’ arguments that the unjust enrichment claim had to be dismissed because, among other things, Plaintiff failed to explain the “benefit” to which it was entitled, and Plaintiffs claim was governed by the express terms of the Agreements. Sept. 26 Order at 17-18. The first argument misstated the pleadings, and the second was inapposite, because parties to a contract have no unjust enrichment' claims if the contract expressly defines their rights. Cal. Med. Ass’n, Inc. v. Aetna U.S. Healthcare of Cal., Inc.,
First, Defendants challenge Plaintiffs citation to cases finding unjust enrichment where funds specifically designated for the plaintiff were taken or diverted by an agent who was to make the payment to the plaintiff. See, e.g., Lectrodryer v. Seoulbank,
Second, Plaintiffs other cases are inap-posite not just because, as Defendant Wig-gans contends, they involve extra-contractual harm and do not require contract interpretation, but because they depend on the ruling courts’ balancing of equities in determining whether plaintiffs' had stated claims for unjust enrichment. See, e.g., McKesson HBOC, Inc. v. N.Y. State Common Ret. Fund, Inc.,
These cases do not state maxims about when plaintiffs can recover under an unjust enrichment theory. They under
Moreover, the availability of legal remedies against other parties — Corthera or Novartis — counsels against the Court’s application of an equitable remedy against defendants who are, in most cases, protected by the corporate form. See McKesson HBOC,
The Court DISMISSES Plaintiffs unjust enrichment claim WITH PREJUDICE, since the Court finds that amendment would be futile.
V. CONCLUSION
For the reasons described above, the Court GRANTS both motions to dismiss Plaintiff Florey Institute of Neuroscience and Mental Health’s complaint. Plaintiffs claims are DISMISSED WITH PREJUDICE.
IT IS SO ORDERED.
Notes
. The FAC adds Defendants KPCB Holdings, Inc.; Domain Partners V, L.P.; DP V Associates, L.P.; Domain Partners VII, L.P.; DP VII Associates, L.P.; Lowell Sears (individually and as trustee); and Caxton Advantage Life Sciences Fund, L.P. The parties and the Court
. ECF Nos. 70 ("Opp’n to KPCB”), 74 ("Reply to KPCB”), 79 ("Opp'n to Wiggans MTD”), 80 ("Wiggans Reply”).
. Both motions to dismiss also include requests to strike portions of the FAC. Since the Court has granted the motions to dismiss, the motions to strike are DENIED AS MOOT.
. Collectively, the 1998 Agreement and 2003 Amendment are the “Agreements.”
. To the extent Defendants contend that they did in fact provide notice to Plaintiff pursuant to Section 6.6(b), that is a factual dispute not suitable for decision on a motion to dismiss because Plaintiff denies receiving notice.
. Defendant Wiggans argues that Plaintiffs latter position is an improper attemp't to amend its pleadings through an opposition brief. Wiggans Reply at 8-10; Reply at 9-12. The Court disregards the procedural argument because, as the parties’ briefs explain, the merits of Plaintiff's equitable lien theory are resolvable at this time.